pipette
ESEspañol

A national ecosystem for long-read genome sequencing: Integrating population genomics and rare disease diagnostics in Sweden

A. Ameur, F. Taylan, M. Ek, J. Eisfeldt, S. Häggqvist, M. Pettersson, I. Bunikis, J. Klar, M. Strandh, R. Josefson, M. Barbaro, A. Beskow, A. Blomberg, M.-L. Bondeson, D. Carlberg, P. Corcoran, I. Duba, R. Ellegard, G. Engström, T. Fall, C. Frykholm, M. Gallardo, S. Gruvberger Saal, A. Gummesson, P. Gustafsson, A. Hagwall, J. Hallin, J. Heintz, H. T. Helgadottir, S. Hellstedt Kerje, V. Henmyr, O. J. Henry, I. Höijer, S. Ivarsson, A. Jemt, T. Jernberg, A. Johansson, M. J. Soller, L. Jonsäll, T. Jonson, F. Jonsson, K. Karrman, A. Kashyap, A. Koc, K

PreprintReal-world use

In the authors' words

To evaluate the clinical implementation of long-read genome sequencing (lrGS) and establish the population reference resources needed to support its use in diagnostics, we integrate two complementary initiatives: Genome of Sweden (GoS), Sweden's contribution to Genome of Europe (GoE), and the Genomic Medicine Sweden - Rare Diseases (GMS-RD) long-read sequencing pilot. The initial GoS release of 576 individuals provides population-scale maps of genetic and epigenetic variation. Among 485 GMS-RD probands, 161 (33.2%) receive a molecular diagnosis, with lrGS providing added clinical value in 40 (24.8%). As a first-line test, lrGS could have avoided at least 42 follow-up analyses and an additional testing cycle in 7.2% of probands, reducing costs and the burden on patients. By integrating population and clinical long-read genomics, Sweden establishes a national ecosystem for genomic research and clinical diagnostics. Our findings support the clinical implementation of lrGS and offer a scalable model for national collaboration.

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, October 14. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.09.26365121